Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Accumulated Expenses (2016 - 2025)

Regenxbio has reported Accumulated Expenses over the past 12 years, most recently at $17.4 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $17.4 million for Q4 2025, down 1.07% from a year ago — trailing twelve months through Dec 2025 was $17.4 million (down 1.07% YoY), and the annual figure for FY2025 was $17.4 million, down 1.07%.
  • Accumulated Expenses for Q4 2025 was $17.4 million at Regenxbio, up from $15.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for RGNX hit a ceiling of $50.5 million in Q2 2023 and a floor of $8.1 million in Q1 2024.
  • Median Accumulated Expenses over the past 5 years was $38.6 million (2021), compared with a mean of $31.3 million.
  • Biggest five-year swings in Accumulated Expenses: surged 521.34% in 2021 and later crashed 82.08% in 2023.
  • Regenxbio's Accumulated Expenses stood at $19.8 million in 2021, then surged by 135.75% to $46.8 million in 2022, then grew by 6.22% to $49.7 million in 2023, then plummeted by 64.58% to $17.6 million in 2024, then decreased by 1.07% to $17.4 million in 2025.
  • The last three reported values for Accumulated Expenses were $17.4 million (Q4 2025), $15.1 million (Q3 2025), and $35.6 million (Q2 2025) per Business Quant data.